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March 7, 2006:1082–90latelet activation in these individuals (3) (Fig. 1). A similar
attern was also seen for soluble P-selectin, reflecting both
ndothelial cell and platelet activation (2,3) (Fig. 1).
High levels of hs-CRP (odds ratio [OR] for CAD: 1.89 [95%
onfidence interval (CI) 1.06 to 3.33], p  0.031), high levels of
-selectin (OR: 1.11 [95% CI 1.03 to 1.20], p  0.009), and low
asodillatory responses to Ach (OR: 0.96 [95% CI 0.91 to 0.99],
 0.035) were all independently associated with CAD in the
ow-risk group. In the high-risk group, high levels of IL-10 were
ndependently associated with a normal coronary angiography
OR: 0.035 [95% CI 0.002 to 0.50], p  0.01), and high levels of
CD40L were associated with CAD (OR: 6.57 [95% CI 2.00 to
13.1], p  0.02).
In contrast to the increased levels of inflammatory markers in those
ith CAD, we found that the only group with raised levels of the
nti-inflammatory cytokine IL-10 was that with hypercholesterolemia
nd normal coronary angiograms. This group also had particularly low
atios of TNF-alpha/IL-10, suggesting anti-inflammatory net effect
n this “high-risk” group without CAD. Interleukin-10 has been
ound to inhibit the release of inflammatory cytokines, tissue factor,
nd matrix metalloproteinases from leukocyte subsets in CAD pa-
ients, possibly promoting plaque stabilization in these patients (4–5).
hese findings suggest an attenuating role of IL-10 in atherogenesis,
ossibly involving protective effect on the endothelium. Indeed, we
ound that the raised IL-10 levels in patients with hypercholesterol-
mia and normal coronary angiograms were accompanied by pre-
erved endothelial function. Such a role has also been shown in various
nimal models, and IL-10 has recently been proposed as an “immu-
ological scalpel” in the atherosclerotic process (5). Our findings
erein suggest that IL-10 also could represent a protective phenotype
igure 2. Plasma levels of high-sensitivity C-reactive protein (hsCRP),
umor necrosis factor (TNF)-, interleukin (IL)-10, and the tumor necrosis
actor-/interleukin-10 ratio in 93 patients in relation to plasma choles-
erol levels (i.e., low-density lipoprotein [LDL] cholesterol 2.7 mmol/l
r 4.5 mmol/l) and results of coronary angiography (i.e., with [] or
ithout [] coronary artery disease [CAD]). *p  0.05 versus subjects
t similar LDL cholesterol level. **p  0.01 versus all three other groups.
p  0.05 versus all three other groups. Data are mean  SEM. HDL 
igh-density lipoprotein.n those individuals with high LDL levels who do not develop CAD. bTorbjørn Holm, MD, PhD
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etters to the Editor
athophysiology of Stent
hrombosis: Platelet Activation,
echanical Factors, or Both?
e read with great interest the elegant study of Wenaweser et al.
1) demonstrating impaired response to antiplatelet therapy in
atients suffering stent thrombosis (ST). Notably, response to
cetylsalicylic acid was impaired in these patients, and additional
lopidogrel therapy failed to overcome the enhanced platelet
ggregation as compared with that found in patients with unevent-
ul coronary stenting or normal volunteers.
The relevance of antiplatelet therapy to prevent in this dreadful
omplication appears clear. However, the other potential major
layer in the field, namely a stent-related mechanical problem, was
ot adequately addressed by these investigators. Therefore, owing
o the potential clinical implication of this study (1) additional
nformation would be most useful. First, it would be important to
now whether all patients presented an optimal angiographic result
fter the procedure or whether suboptimal results could be de-
ected immediately after stenting. Information on vessel size and
alloon/artery ratio would be of interest in this regard.
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1087JACC Vol. 47, No. 5, 2006 Correspondence
March 7, 2006:1082–90Second, we previously demonstrated that intravascular ultra-
ound is able to depict significant underlying mechanical problems
n most patients with ST (stent underexpansion, malapposition,
issections, inflow/outflow stenoses) (2). Because these findings,
hich require specific therapy, are frequently undetected by angiog-
aphy, a description of the ultrasonic data of these patients (if
vailable) would be helpful. Third, information on the reason for
nitial stent implantation would be appreciated because it has been
uggested that acute coronary syndromes (with the associated
latelet hyperactivity) may be a predisposing factor for ST (2).
Moreover, detailing whether some episodes of ST were second-
ry to antiplatelet therapy withdrawal would also be of great
nterest.
Finally, considering the potentially catastrophic consequences of
ecurrent ST, it would be important to define precisely when
lopidogrel therapy was discontinued in the study in order to
valuate platelet aggregation with aspirin alone. The potential
enefit of a higher dose of clopidogrel has been suggested (3,4),
nd this strategy appears especially attractive for high-risk patients.
herefore, from a pragmatic standpoint, it will be critical to
etermine whether the relative inefficacy of a conventional clopi-
ogrel regimen (1) can be overcome with higher doses (3,4).
ventually, unraveling the multifaceted etiology of ST is urgently
equired to prevent and successfully treat this challenging problem.
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EPLY
e thank Dr. Alfonso for his interest in our work (1). We agree
ith him that the phenomenon of “stent thrombosis” is a multi-
actoral process and that mechanical factors play an important role,
specially in the setting of an acute stent thrombosis (within 24 h),
hereas for subacute (1 to 30 days) or late stent thrombosis (30
ays) a more complex etiology has been postulated. In our case-
ontrol study no patient with an acute stent thrombosis was
ncluded (1). Platelet aggregation was assessed several months aftertent thrombosis to avoid confounding factors such as platelet
ctivation induced by thrombotic stent occlusion. Dr. Alfonso cites
our issues in his letter. We address each one here.
First, we fully agree that an optimal angiographic result is a key
actor in the prevention of stent thrombosis (2). In our study
opulation two patients showed a suboptimal angiographic result
one had a distal residual dissection with Thrombolysis In Myo-
ardial Infarction [TIMI] flow grade 2; another showed a no-
eflow phenomenon).
Second, intravascular ultrasound was not routinely performed
fter stent implantation in our institution. Therefore, we cannot
xclude stent underexpansion or stent malapposition.
Third, acute coronary syndromes have been previously identi-
ed as potential risk factors for stent thrombosis (2,3). In our study
opulation, 83% of the patients in the stent thrombosis group
uffered from an acute coronary syndrome at time of stent
mplantation, whereas only 43% of patients in the control group
ere affected (p  0.001). This highlights the importance of
ctivated platelets in the setting of an acute coronary syndrome and
he role of an effective antithrombotic regimen in the prevention of
tent thrombosis. Therefore, a resistance to antiplatelet therapy
ay represent an additional risk factor for stent thrombosis.
Fourth, all patients in our study population were on lifelong
spirin therapy; however, at the time of stent thrombosis 26% were
ff thienopyridine treatment. We agree that this may be another
isk factor, although the rate of clopidogrel resistance was lowest in
tent thrombosis patients. According to our protocol all patients
ere first examined under aspirin therapy alone, followed by a
econd measurement under aspirin and clopidogrel.
Finally, the etiology of stent thrombosis is multifaceted, and we
gree that mechanical risk factors should be avoided. Nevertheless,
he efficacy of our standard (dual) antiplatelet treatment might not
e as good as wished for. A higher dose of clopidogrel or new
ntithrombotic drugs as alternative treatment in patients with
esistance to antiplatelet therapy warrant further evaluation to
revent stent thrombosis and its high morbidity and mortality.
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